BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
23 hedge funds and large institutions have $4.28M invested in BRAINSTORM CELL THERAPUTC in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
10% more funds holding
Funds holding: 21 → 23 (+2)
3% less capital invested
Capital invested by funds: $4.39M → $4.28M (-$113K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$83.4K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.4K |
| 3 |
LPL Financial
San Diego,
California
|
+$27.5K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$8.24K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$916K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$227K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.68K |
BCLI Hedge Fund Activity: Q4 2015 in Review
23 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q4 2015, worth a combined $4.28M — down 2.6% from $4.39M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BCLI positions and 3 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $83.4K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $916K sold.
- 23 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q4 2015, up from 21 in Q3 2015.
- Funds reported $4.28M of BRAINSTORM CELL THERAPUTC stock for Q4 2015, down 2.6% quarter-over-quarter.
- 5 funds opened new BRAINSTORM CELL THERAPUTC positions in Q4 2015 and 3 closed out, a net change of +2 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q4 2015 was A.R.T. Advisors, an estimated $83.4K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q4 2015 was Perceptive Advisors, an estimated $916K sold.
Based on aggregated 13F filings for Q4 2015.